{"id":65795,"date":"2026-05-20T13:50:44","date_gmt":"2026-05-20T05:50:44","guid":{"rendered":"https:\/\/flcube.com\/?p=65795"},"modified":"2026-05-20T13:50:45","modified_gmt":"2026-05-20T05:50:45","slug":"china-population-welfare-foundation-and-lilly-china-launch-tuohu-changan-patient-assistance-program-for-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65795","title":{"rendered":"China Population Welfare Foundation and Lilly China Launch &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program for Inflammatory Bowel Disease"},"content":{"rendered":"\n<p>The <strong>China Population Welfare Foundation<\/strong>, in partnership with <strong>Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) China<\/strong>, unveiled this week the <strong>&#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program<\/strong>, designed to address financial barriers and improve access to innovative therapies for adults with <strong>moderate to severe active inflammatory bowel disease (IBD)<\/strong>. The program will provide eligible patients with access to <strong>Omvoh (mirikizumab)<\/strong> and its <strong>subcutaneous formulation<\/strong>, with a scheduled launch in <strong>June 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-overview\">Program Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Initiative<\/strong><\/td><td>&#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program<\/td><\/tr><tr><td><strong>Lead Organization<\/strong><\/td><td>China Population Welfare Foundation<\/td><\/tr><tr><td><strong>Corporate Partner<\/strong><\/td><td>Lilly China<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Adults with moderate to severe active IBD<\/td><\/tr><tr><td><strong>Therapies Provided<\/strong><\/td><td>Omvoh (mirikizumab) and Omvoh subcutaneous formulation<\/td><\/tr><tr><td><strong>Launch Date<\/strong><\/td><td>June 2026<\/td><\/tr><tr><td><strong>Eligibility Criteria<\/strong><\/td><td>Medical and financial requirements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-burden-amp-market-context\">Disease Burden &amp; Market Context<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ibd-epidemiology-in-china\">IBD Epidemiology in China<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Condition<\/th><th>Prevalence Rate<\/th><th>Comparative Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Ulcerative Colitis (UC)<\/strong><\/td><td>17.24 per 100,000 people<\/td><td>~5x higher than Crohn&#8217;s disease<\/td><\/tr><tr><td><strong>Crohn&#8217;s Disease (CD)<\/strong><\/td><td>3.39 per 100,000 people<\/td><td>Growing at accelerated rate<\/td><\/tr><tr><td><strong>Trend<\/strong><\/td><td>Significant increase over past two decades<\/td><td>Emerging as major gastroenterology concern<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatment-access-challenges\">Treatment Access Challenges<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Financial Barriers:<\/strong> High out-of-pocket costs limit access to precision targeted therapies despite clinical availability<\/li>\n\n\n\n<li><strong>Treatment Delays:<\/strong> Patients experience significant delays in accessing innovative treatment options due to economic constraints<\/li>\n\n\n\n<li><strong>Healthcare Disparities:<\/strong> Geographic and socioeconomic factors create uneven access to specialized IBD care<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Despite advancement to precision medicine era, substantial patient population remains underserved<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-profile-omvoh-mirikizumab\">Therapeutic Profile \u2013 Omvoh (mirikizumab)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Monoclonal antibody targeting IL-23 pathway<\/li>\n\n\n\n<li><strong>Formulations:<\/strong> Intravenous and subcutaneous delivery options<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Moderate to severe active IBD (UC and CD)<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> Precision targeted therapy with demonstrated efficacy in refractory IBD populations<\/li>\n\n\n\n<li><strong>Access Strategy:<\/strong> Patient assistance program bridges gap between regulatory approval and real-world accessibility<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-impact-amp-healthcare-implications\">Strategic Impact &amp; Healthcare Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Public Health Impact<\/strong><\/td><td>Addresses growing burden of chronic IBD in Chinese population<\/td><\/tr><tr><td><strong>Healthcare Equity<\/strong><\/td><td>Reduces financial barriers for economically disadvantaged patients<\/td><\/tr><tr><td><strong>Quality of Life<\/strong><\/td><td>Enables consistent access to effective therapies, improving long-term outcomes<\/td><\/tr><tr><td><strong>Healthcare System Efficiency<\/strong><\/td><td>Prevents costly complications and hospitalizations through improved disease control<\/td><\/tr><tr><td><strong>Innovation Adoption<\/strong><\/td><td>Accelerates uptake of precision medicine approaches in real-world settings<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-program-implementation-framework\">Program Implementation Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Identification:<\/strong> Collaboration with gastroenterology centers nationwide for patient screening and referral<\/li>\n\n\n\n<li><strong>Eligibility Verification:<\/strong> Dual assessment of medical necessity and financial need<\/li>\n\n\n\n<li><strong>Distribution Network:<\/strong> Integrated supply chain ensuring reliable medication access across geographic regions<\/li>\n\n\n\n<li><strong>Monitoring &amp; Evaluation:<\/strong> Outcomes tracking to measure program effectiveness and patient benefit<\/li>\n\n\n\n<li><strong>Sustainability Model:<\/strong> Public-private partnership structure ensures long-term program viability<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program, including implementation timelines, patient access objectives, and therapeutic outcomes. Actual results may differ materially due to risks including regulatory requirements, patient enrollment rates, funding availability, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,911],"class_list":["post-65795","post","type-post","status-publish","format-standard","hentry","category-company","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Population Welfare Foundation and Lilly China Launch &quot;Tuohu Chang&#039;an&quot; Patient Assistance Program for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the &quot;Tuohu Chang&#039;an&quot; Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65795\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Population Welfare Foundation and Lilly China Launch &quot;Tuohu Chang&#039;an&quot; Patient Assistance Program for Inflammatory Bowel Disease\" \/>\n<meta property=\"og:description\" content=\"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the &quot;Tuohu Chang&#039;an&quot; Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65795\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T05:50:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T05:50:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Population Welfare Foundation and Lilly China Launch &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program for Inflammatory Bowel Disease\",\"datePublished\":\"2026-05-20T05:50:44+00:00\",\"dateModified\":\"2026-05-20T05:50:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65795#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65795\",\"name\":\"China Population Welfare Foundation and Lilly China Launch \\\"Tuohu Chang'an\\\" Patient Assistance Program for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-20T05:50:44+00:00\",\"dateModified\":\"2026-05-20T05:50:45+00:00\",\"description\":\"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the \\\"Tuohu Chang'an\\\" Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65795\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65795#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Population Welfare Foundation and Lilly China Launch &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program for Inflammatory Bowel Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Population Welfare Foundation and Lilly China Launch \"Tuohu Chang'an\" Patient Assistance Program for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry","description":"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the \"Tuohu Chang'an\" Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65795","og_locale":"en_US","og_type":"article","og_title":"China Population Welfare Foundation and Lilly China Launch \"Tuohu Chang'an\" Patient Assistance Program for Inflammatory Bowel Disease","og_description":"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the \"Tuohu Chang'an\" Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.","og_url":"https:\/\/flcube.com\/?p=65795","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-20T05:50:44+00:00","article_modified_time":"2026-05-20T05:50:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65795#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65795"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Population Welfare Foundation and Lilly China Launch &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program for Inflammatory Bowel Disease","datePublished":"2026-05-20T05:50:44+00:00","dateModified":"2026-05-20T05:50:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65795"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","NYSE: LLY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65795#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65795","url":"https:\/\/flcube.com\/?p=65795","name":"China Population Welfare Foundation and Lilly China Launch \"Tuohu Chang'an\" Patient Assistance Program for Inflammatory Bowel Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-20T05:50:44+00:00","dateModified":"2026-05-20T05:50:45+00:00","description":"The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week the \"Tuohu Chang'an\" Patient Assistance Program, designed to address financial barriers and improve access to innovative therapies for adults with moderate to severe active inflammatory bowel disease (IBD). The program will provide eligible patients with access to Omvoh (mirikizumab) and its subcutaneous formulation, with a scheduled launch in June 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65795#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65795"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65795#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Population Welfare Foundation and Lilly China Launch &#8220;Tuohu Chang&#8217;an&#8221; Patient Assistance Program for Inflammatory Bowel Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65795"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65795\/revisions"}],"predecessor-version":[{"id":65796,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65795\/revisions\/65796"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}